<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04027088</url>
  </required_header>
  <id_info>
    <org_study_id>2018/548</org_study_id>
    <nct_id>NCT04027088</nct_id>
  </id_info>
  <brief_title>Effect of Preoperative Immunonutrition in Upper Digestive Tract</brief_title>
  <official_title>Multicenter Randomized Clinical Trial of the Effect of Preoperative Immunonutrition Versus Standard Enteral Nutrition in Elective Oncological Surgery of the Upper Digestive Tract</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Complexo Hospitalario Universitario de A Coruña</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Complexo Hospitalario Universitario de A Coruña</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double-blind, multicenter clinical trial that will evaluate the effects of
      immuno-nutrition in the preoperative period in patients with cancer of the upper digestive
      tract (esophagus, stomach, and pancreas). The aim is to compare the specific effect of the
      immunonutrients respect to an equivalent formula in caloric-protein value but without
      immunonutrients, in the surgical evolution of the cancer patient.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

      Perioperative nutritional status is a key factor in the evolution, as well as, postoperative
      morbidity and mortality of cancer patients. Particularly, digestive neoplasms have a high
      risk of malnutrition and this is related to a higher rate of surgery complications and
      mortality in the postoperative period. The immunonutrition seems to modulate the immune
      system and the inflammatory response in patients operated on for digestive neoplasia.
      However, the results to date are controversial.

      Aim:

      To compare the effect of an immunomodulatory oral nutritional supplement (enriched in
      arginine, nucleotides, omega 3 fatty acids, olive oil polyphenols, L-carnitine, and
      antioxidants) against an equivalent in protein-energy without immunonutrients, administrated
      in the preoperative period, in the surgical evolution of the cancer patient with neoplasia of
      the upper digestive tract.

      Methods:

      It is a randomized, double-blind, multicenter clinical trial. 178 patients with neoplasms of
      the esophagus, stomach or pancreas, with indication of surgical treatment, will be included.
      The patients will be randomized into two groups (intervention group and control group) and
      both will receive 2 daily bricks of the assigned formula (with or without immunonutrients,
      respectively) 5 days prior to surgery. The main variables of the study are: appearance of
      infectious or noninfectious complications in the postoperative period, length of hospital
      stay, and mortality. These variables will be compared by group (immunonutrition vs. non
      immunonutrition).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 10, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infectious complications</measure>
    <time_frame>Up to 30 days post-operative</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Surgical fistulas</measure>
    <time_frame>Up to 30 days post-operative</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Up to 30 days post-operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>Up to 30 days post-operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight loss</measure>
    <time_frame>10 days Pre-operative</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">178</enrollment>
  <condition>Immunonutrition</condition>
  <condition>Gastric Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <condition>Pancreas Cancer</condition>
  <condition>Surgery--Complications</condition>
  <arm_group>
    <arm_group_label>Immunonutrition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral nutritional supplement: hypercaloric and hyperproteic with immunonutrients: Arginine, nucleotides, omega-3, olive oil polyphenols, antioxidants and L-carnitine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral nutritional supplement: hypercaloric and hyperproteic without immunonutrients</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Immunonutrition</intervention_name>
    <description>It is a hypercaloric and hyperproteic dietary supplement formulated with immunonutrients: Arginin, nucleotides, omega-3, olive oil polyphenols, antioxidants and L-carnitine</description>
    <arm_group_label>Immunonutrition</arm_group_label>
    <other_name>Bi1 procare</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Standard</intervention_name>
    <description>It is a hypercaloric and hyperproteic dietary supplement formulated without immunonutrients</description>
    <arm_group_label>Standard</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of cancer of esophagus, stomach and / or pancreas, at any stage, proposed
             for surgery

          -  Signing informed consent

        Exclusion Criteria:

          -  Pregnant or breastfeeding

          -  Advanced renal insufficiency prior to dialysis (GFR &lt;25 ml / min)

          -  Allergy or intolerance to any of the components of the dietary supplement (including
             fish allergy)

          -  Patients with contraindications for enteral nutrition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel Á Martínez-Olmos, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complexo Hospitalario Universitario de Santiago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alfonso Vidal-Casariego, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complexo Hospitalario Universitario de A Coruña</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alfonso Vidal-Casariego, PhD, MD</last_name>
    <phone>+34981176442</phone>
    <email>alfonso.vidal.casariego@sergas.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Miguel A. Martínez Olmos</name>
      <address>
        <city>Santiago De Compostela</city>
        <state>A Coruña</state>
        <zip>15701</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel A Martínez Olmos, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Miguel A Martínez Olmos, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana Cantón Blanco, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rocío Villar Taibo, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alicia Santamaría Nieto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana B Crujeiras, BSc PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana Suárez Rodríguez, BSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alfonso Vidal-Casariego</name>
      <address>
        <city>A Coruña</city>
        <state>La Coruna</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfonso Vidal-Casariego, MD, PhD</last_name>
      <phone>+34981176442</phone>
      <email>alfonso.vidal.casariego@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Alfonso Vidal-Casariego, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisco Pita-Gutiérrez, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gloria Lugo-Rodríguez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 16, 2019</study_first_submitted>
  <study_first_submitted_qc>July 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2019</study_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Complexo Hospitalario Universitario de A Coruña</investigator_affiliation>
    <investigator_full_name>Alfonso Vidal Casariego</investigator_full_name>
    <investigator_title>Dr. Alfonso Vidal Casariego, MD PhD</investigator_title>
  </responsible_party>
  <keyword>immunonutrition</keyword>
  <keyword>surgery</keyword>
  <keyword>postoperative complications</keyword>
  <keyword>length of hospital stay</keyword>
  <keyword>nutritional status</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

